Skip to NavigationSkip to content

Patient dies after receiving faecal transplant

Published on 17/06/19 at 09:29am

A person has died after experiencing an adverse event related to a faecal transplant.

The FDA has warned that two immunocompromised patients developed invasive infections caused by multi drug resistant bacteria, after receiving a faecal transplant.

The patients were infected with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E.coli) after receiving faecal microbiota for transplantation (FMT) from the same donor.

The donor stool and resulting FMT used in these two individuals were not tested for ESBL-producing gram-negative organisms prior to use.

Both patients then developed antibiotic resistant E.Coli infections. One of the patients subsequently died.

FMT is an experimental treatment Clostridium difficile, a bacterial infection which causes severe diarrhoea.

“While we support this area of scientific discovery, it’s important to note that FMT does not come without risk,” said Dr Peter Marks, director of FDA’s Center for Biologics Evaluation and Research.

“We’ve become aware of infections with multi-drug resistant organisms after patients received investigational FMT, including one patient death. We therefore want to alert all health care professionals who administer FMT about this potential serious risk so they can inform their patients.”

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches